Non-invasive iontophoretic delivery of peptides and proteins across the skin

Expert Opinion on Drug Delivery

Volumn 8, Issue 5, 2011, Pages 645-663

  Gratieri, Taís ^a   Kalaria, Dhaval ^a   Kalia, Yogeshvar N ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

iontophoresis; non invasive; peptide and protein therapeutics; skin; topical; transdermal

Indexed keywords

BOTULINUM TOXIN A; CALCITONIN; DESMOPRESSIN; DRUG CARRIER; GONADORELIN; GROWTH HORMONE RELEASING FACTOR; INSULIN; LEUPRORELIN; NAFARELIN; OCTREOTIDE; PARATHYROID HORMONE; PEPTIDES AND PROTEINS; RIBONUCLEASE; SOMATOSTATIN; TRIPTORELIN; VAPREOTIDE; VASOPRESSIN;

COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG TRANSPORT; ELECTRODE; ELECTROOSMOSIS; HUMAN; HYDROPHILICITY; HYPERCALCEMIA; ION TRANSPORT; IONTOPHORESIS; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PAGET BONE DISEASE; PANCREAS ISLET BETA CELL; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SKIN; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; DRUG COMPOUNDING; HUMANS; IONTOPHORESIS; PEPTIDES; PROTEINS; SKIN;

EID: 79955085943     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.566265     Document Type: Review

References (159)

1. Reichert J. Development trends for peptide therapeutics - A comprehensive quantitative analysis of peptide therapeutics in clinical development. Available from: www peptidetherapeutics org [Last accessed 30 September 2010]
2. Zompra AA, Galanis AS, Werbitzky O, Albericio F. Manufacturing peptides as active pharmaceutical ingredients. Fut Med Chem 2009;1:361-77
3. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010;15:40-56
4. Pichereau C, Allary C. Therapeutic peptides under the spotlight. Eur BioPharm Rev 2005:88-93
5. Ayoub M, Scheidegger D. Peptide drugs, overcoming the challenges, a growing business. Chim Oggi 2006;24:46-8 (Pubitemid 44475342)
6. Haberkorn U, Eisenhut M. Molecular imaging and therapy - a programme based on the development of new biomolecules. Eur J Nucl Med Mol Imaging 2005;32:1354-9 (Pubitemid 41746836)
7. Yuan L, Kurek I, English J, Keenan R. Laboratory-directed protein evolution. Microbiol Mol Biol Rev 2005;69:373-92 (Pubitemid 41306743)
8. Ovadia O, Greenberg S, Laufer B, et al. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin Drug Discov 2010;5:655-71
9. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006;30:351-67 (Pubitemid 43886897)
10. Chaturvedula A, Joshi DP, Anderson C, et al. In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. Int J Pharm 2005;297:190-6 (Pubitemid 40720279)
11. Zhang Q, Grice JE, Wang GJ, Roberts MS. Cutaneous metabolism in transdermal drug delivery. Curr Drug Metab 2009;10:227-35
12. Schuetz YB, Naik A, Guy RH, et al. Transdermal iontophoretic delivery of triptorelin in vitro. J Pharm Sci 2005;94:2175-82 (Pubitemid 41665278)
13. Green PG. Iontophoretic delivery of peptide drugs. J Control Release 1996;41:33-48 (Pubitemid 26246361)
14. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004;56:619-58 (Pubitemid 38326937)
15. Burnette RR, Marrero D.comparison between the iontophoretic and passive transport of thyrotropin releasing hormone across excised nude mouse skin. J Pharm Sci 1986;75:738-43 (Pubitemid 16016528)
16. Marchand JE, Hagino N. Effect of iontophoresis of vasopressin on lateral septal neurons. Exp Neurol 1982;78:790-5 (Pubitemid 13221071)
17. Siddiqui O, Sun Y, Liu JC, Chien YW. Facilitated transdermal transport of insulin. J Pharm Sci 1987;76:341-5 (Pubitemid 17118167)
18. Stephen RL, Petelenz TJ, Jacobsen SC. Potential novel methods for insulin administration: I. Iontophoresis. Biomed Biochim Acta 1984;43:553-8 (Pubitemid 14000632)
19. Subramony JA, Sharma A, Phipps JB. Microprocessor controlled transdermal drug delivery. Int J Pharm 2006;317:1-6 (Pubitemid 43866349)
20. Phipps JB, Padmanabhan RV, Lattin GA. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 1989;78:365-9 (Pubitemid 20070543)
21. Abla N, Naik A, Guy RH, Kalia YN. Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. J Control Release 2005;108:319-30 (Pubitemid 41608664)
22. Delgado-Charro MB, Guy RH. Transdermal iontophoresis for controlled drug delivery and non-invasive monitoring. STP Pharm Sci 2001;11:403-14 (Pubitemid 34016285)
23. Phipps JB, Gyory JR. Transdermal ion migration. Adv Drug Deliv Rev 1992;9:137-76
24. Sage BH, Riviere JE. Model systems in iontophoresis transport efficacy. Adv Drug Deliv Rev 1992; 9: 265-87
25. Mudry B, Guy RH, Begona Delgado-Charro M. Prediction of iontophoretic transport across the skin. J Control Release 2006;111:362-7
26. Mudry B, Guy RH, Delgado-Charro MB. Transport numbers in transdermal iontophoresis. Biophys J 2006;90:2822-30
27. Mudry B, Guy RH, Delgado-Charro MB. Electromigration of ions across the skin: determination and prediction of transport numbers. J Pharm Sci 2006;95:561-9
28. Kasting GB, Keister JC. Application of electrodiffusion theory for a homogeneous membrane to iontophoretic transport through skin. J Control Release 1989;8:195-210 (Pubitemid 19098999)
29. Marro D, Guy RH, Delgado-Charro MB. Characterization of the iontophoretic permselectivity properties of human and pig skin. J Control Release 2001;70:213-17 (Pubitemid 32144805)
30. Pikal MJ, Shah S. Transport mechanisms in iontophoresis. 3. An experimental-study of the contributions of electroosmotic flow and permeability change in transport of low and high-molecular-weight solutes. Pharm Res 1990;7:222-9 (Pubitemid 20228559)
31. Pikal MJ. Transport mechanisms in iontophoresis. 1. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res 1990;7:118-26 (Pubitemid 20208062)
32. Pikal MJ, Shah S. Transport mechanisms in iontophoresis. 2. Electroosmotic flow and transference number measurements for hairless mouse skin. Pharm Res 1990;7:213-21 (Pubitemid 20228558)
33. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev 2001;46:281-305
34. Green PG, Hinz RS, Kim A, et al. Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharm Res 1991;8:1121-7
35. Cazares-Delgadillo J, Naik A, Ganem-Rondero A, et al. Transdermal delivery of cytochrome C-A 12.4 kDa protein-Across intact skin by constant-current iontophoresis. Pharm Res 2007;24:1360-8 (Pubitemid 46870601)
36. Schuetz YB, Naik A, Guy RH, et al. Transdermal iontophoretic delivery of vapreotide acetate across porcine skin in vitro. Pharm Res 2005;22:1305-12 (Pubitemid 41176034)
37. Schuetz YB, Naik A, Guy RH, Kalia YN. Effect of amino acid sequence on transdermal iontophoretic peptide delivery. Eur J Pharm Sci 2005;26:429-37 (Pubitemid 41551576)
38. Hirvonen J, Kalia YN, Guy RH. Transdermal delivery of peptides by iontophoresis. Nat Biotechnol 1996;14:1710-13 (Pubitemid 26414817)
39. Guy RH, Kalia YN, Delgado-Charro MB, et al. Iontophoresis: electrorepulsion and electroosmosis. J Control Release 2000;64:129-32 (Pubitemid 30035313)
40. Dubey S, Kalia YN. Non-invasive iontophoretic delivery of enzymatically active ribonuclease A (13.6 kDa) across intact porcine and human skins. J Control Release 2010;145:203-9
41. Chang SL, Hofmann GA, Zhang L, et al. Stability of a transdermal salmon calcitonin formulation. Drug Deliv 2003;10:41-5 (Pubitemid 36205996)
42. Patel SR, Zhong H, Sharma A, Kalia YN. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm 2007;66:296-301 (Pubitemid 46661905)
43. Patel SR, Zhong H, Sharma A, Kalia YN. Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur J Pharm Biopharm 2009;72:304-9
44. Lau DT, Sharkey JW, Petryk L, et al. Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin) in the rabbit. Pharm Res 1994;11:1742-6 (Pubitemid 24377085)
45. Green P, Shroot B, Bernerd F, et al. In vitro and in vivo iontophoresis of a tripeptide across nude rat skin. J Control Release 1992;20:209-18
46. Craane-Vanhinsberg WHM, Bax L, Flinterman NHM, et al. Iontophoresis of a model peptide across human skin in-vitro - Effects of iontophoresis protocol, pH, and ionic strength on peptide flux and skin impedance. Pharm Res 1994;11:1296-300 (Pubitemid 24287409)
47. Ledger PW. Skin biological issues in electrically enhanced transdermal delivery. Adv Drug Deliv Rev 1992;9:289-307
48. Huang YY, Wu SM, Wang CY. Response surface method: a novel strategy to optimize iontophoretic transdermal delivery of thyrotropin-releasing hormone. Pharm Res 1996;13:547-52
49. Knoblauch P, Moll F. In-vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis. J Control Release 1993;26:203-12 (Pubitemid 23287365)
50. Kumar S, Hing C, Patel S, et al. Effect of Iontophoresis on in vitro skin permeation of an analog of growth-hormone releasing-factor in the hairless guinea-pig model. J Pharm Sci 1992;81:635-9 (Pubitemid 23006787)
51. Abu Hashim II, Motoyama K, Abd-ElGawad AEH, et al. Potential use of iontophoresis for transdermal delivery of NF-kappa B decoy oligonucleotides. Int J Pharm 2010;393:127-34
52. Kanebako M, Inagi T, Takayama K. Evaluation of skin barrier function using direct current II: effects of duty cycle, waveform, frequency and mode. Biol Pharm Bull 2002;25:1623-8 (Pubitemid 39663682)
53. Prausnitz MR. The effects of electric current applied to skin: a review for transdermal drug delivery. Adv Drug Deliv Rev 1996;18:395-425 (Pubitemid 126338020)
54. Raiman J, Koljonen M, Huikko K, et al. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis. Eur J Pharm Sci 2004;21:371-7 (Pubitemid 38156175)
55. Rodriguez Bayon AM, Guy RH. Iontophoresis of nafarelin across human skin in vitro. Pharm Res 1996;13:798-800 (Pubitemid 26156231)
56. Delgado-Charro MB, Guy RH. Characterization of convective solvent flow during iontophoresis. Pharm Res 1994;11:929-35 (Pubitemid 24227635)
57. Delgado-Charro MB, Rodriguez-Bayon AM, Guy RH. Iontophoresis of Nafarelin - Effects of current density and concentration on electrotransport in vitro. J Control Release 1995;35:35-40
58. Delgado-Charro MB, Guy RH. Iontophoretic delivery of Nafarelin across the skin. Int J Pharm 1995;117:165-72
59. Hirvonen J, Guy RH. Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm Res 1997;14:1258-63 (Pubitemid 27432553)
60. Hoogstraate AJ, Srinivasan V, Sims SM, Higuchi WI. Iontophoretic enhancement of peptides - Behavior of Leuprolide versus model permeants. J Control Release 1994;31:41-7 (Pubitemid 24248115)
61. Lu MF, Lee D, Carlson R, et al. The effects of formulation variables on iontophoretic transdermal delivery of Leuprolide to humans. Drug Dev Ind Pharm 1993;19:1557-71 (Pubitemid 23179148)
62. Nair V, Panchagnula R. Physicochemical considerations in the iontophoretic delivery of a small peptide: in vitro studies using arginine vasopressin as a model peptide. Pharmacol Res 2003;48:175-82 (Pubitemid 36683166)
63. Marro D, Kalia YN, Delgado-Charro MB, Guy RH. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 2001;18:1701-8 (Pubitemid 34020425)
64. Green PG, Hinz RS, Cullander C, et al. Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm Res 1991;8:1113-20
65. Panchagnula R, Bindra P, Kumar N, et al. Stability of insulin under iontophoretic conditions. Pharmazie 2006;61:1014-18 (Pubitemid 46031895)
66. Tokumoto S, Higo N, Sugibayashi K. Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin. Int J Pharm 2006;326:13-19 (Pubitemid 44647740)
67. Levin J, Maibach H. Human skin buffering capacity: an overview. Skin Res Technol 2008;14:121-6 (Pubitemid 351560369)
68. Shukla C, Friden P, Juluru R, Stagni G. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations. J Pharm Sci 2009;98:917-25
69. Delgado-Charro MB. Recent advances on transdermal iontophoretic drug delivery and non-invasive sampling. J Drug Deliv Sci Technol 2009;19:75-88
70. Marro D, Kalia YN, Delgado-Charro MB, Guy RH. Optimizing iontophoretic drug delivery: identification and distribution of the charge-carrying species. Pharm Res 2001;18:1709-13 (Pubitemid 34020426)
71. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001;215:57-65 (Pubitemid 32206604)
72. Haak RP, Gyory JR, Theeuwes F, et al. Iontophoretic delivery device and methods of hydrating same. US5320598; 1994
73. Fang JY, Hsu LR, Huang YB, Tsai YH. Evaluation of transdermal iontophoresis of enoxacin from polymer formulations: in vitro skin permeation and in vivo microdialysis using Wistar rat as an animal model. Int J Pharm 1999;180:137-49
74. Fang JY, Sung KC, Hu OYP, Chen HY. Transdermal delivery of nalbuphine and nalbuphine pivalate from hydrogels by passive diffusion and iontophoresis. Arzneimittelforschung 2001;51:408-13
75. Fang JY, Sung KC, Wang JJ, et al. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels. J Pharm Pharmacol 2002;54:1329-37 (Pubitemid 35174177)
76. Jyoung JY, Shim BS, Cho DE, Hwang IS. Iontophoretic transdermal delivery of alendronate in hairless mouse skin. Polym Korea 2009;33:237-42
77. Taveira SF, Nomizo A, Lopez RFV. Effect of the iontophoresis of a chitosan gel on doxorubicin skin penetration and cytotoxicity. J Control Release 2009;134:35-40
78. Merclin N, Bramer T, Edsman K. Iontophoretic delivery of 5-aminolevulinic acid and its methyl ester using a carbopol gel as vehicle. J Control Release 2004;98:57-65 (Pubitemid 38881607)
79. Banga AK, Chien YW. Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs. Pharm Res 1993;10:697-702 (Pubitemid 23152315)
80. Tatavarti AS, Mehta KA, Augsburger LL, Hoag SW. Influence of methacrylic and acrylic acid polymers on the release performance of weakly basic drugs from sustained release hydrophilic matrices. J Pharm Sci 2004;93:2319-31 (Pubitemid 39129629)
81. Essa EA, Bonner MC, Barry BW. Iontophoretic estradiol skin delivery and tritium exchange in ultradeformable liposomes. Int J Pharm 2002;240:55-66 (Pubitemid 34607702)
82. Fang JY, Sung KC, Lin HH, Fang CL. Transdermal iontophoretic delivery of enoxacin from various liposome-encapsulated formulations. J Control Release 1999;60:1-10 (Pubitemid 29255824)
83. Han I, Kim M, Kim J. Enhanced transfollicular delivery of adriamycin with a liposome and iontophoresis. Exp Dermatol 2004;13:86-92 (Pubitemid 38247866)
84. Vutla NB, Betageri GV, Banga AK. Transdermal iontophoretic delivery of enkephalin formulated in liposomes. J Pharm Sci 1996;85:5-8 (Pubitemid 26029065)
85. Manosroi A, Khositsuntiwong N, Gotz F, et al. Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res 2009;19:91-8
86. Kantaria S, Rees GD, Lawrence MJ. Gelatin-stabilised microemulsion-based organogels: rheology and application in iontophoretic transdermal drug delivery. J Control Release 1999;60:355-65 (Pubitemid 29335960)
87. Sintov AC, Brandys-Sitton R. Facilitated skin penetration of lidocaine: combination of a short-term iontophoresis and microemulsion formulation. Int J Pharm 2006;316:58-67 (Pubitemid 43765688)
88. Liu W, Hu M, Liu W, et al. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm 2008;364:135-41
89. Joo HH, Lee HY, Kim JC, et al. Integrities and skin permeation-enhancing characteristics of behenic acid nanoparticles. J Dispers Sci Technol 2009;30:149-54
90. Li J, Zhai YL, Zhang B, et al. Methoxy poly(ethylene glycol)-block- poly(D, L-lactic acid) copolymer nanoparticles as carriers for transdermal drug delivery. Polym Int 2008;57:268-74 (Pubitemid 351166802)
91. Miyazaki S, Takahashi A, Kubo W, et al. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J Pharm Pharm Sci 2003;6:238-45
92. Luengo J, Weiss B, Schneider M, et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol 2006;19:190-7 (Pubitemid 44114517)
93. Stracke F, Weiss B, Lehr CM, et al. Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs. J Invest Dermatol 2006;126:2224-33 (Pubitemid 44413169)
94. Boinpally RR, Zhou SL, Devraj G, et al. Iontophoresis of lecithin vesicles of cyclosporin A. Int J Pharm 2004;274:185-90 (Pubitemid 38457017)
95. Abla N, Naik A, Guy RH, Kalia YN. Effect of charge and molecular weight on transdermal peptide delivery by iontophoresis. Pharm Res 2005;22:2069-78 (Pubitemid 41821586)
96. Schuetz YB, Carrupt PA, Naik A, et al. Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. Eur J Pharm Sci 2006;29:53-9 (Pubitemid 44294860)
97. Abla N, Geiser L, Mirgaldi M, et al. Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility. J Pharm Sci 2005;94:2667-75 (Pubitemid 43265390)
98. Henchoz Y, Abla N, Veuthey JL, Carrupt PA. A fast screening strategy for characterizing peptide delivery by transdermal iontophoresis. J Control Release 2009;137:123-9
99. Banga AK, Chien YW. Characterization of in-vitro transdermal iontophoretic delivery of insulin. Drug Dev Ind Pharm 1993;19:2069-87 (Pubitemid 23234712)
100. Langkjaer L, Brange J, Grodsky GM, Guy RH. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J Control Release 1998;51:47-56 (Pubitemid 28064644)
101. Pillai O, Panchagnula R. Transdermal iontophoresis of insulin - V. Effect of terpenes. J Control Release 2003;88:287-96 (Pubitemid 36287345)
102. Pillai O, Borkute SD, Sivaprasad N, Panchagnula R. Transdermal iontophoresis of insulin - II. Physicochemical considerations. Int J Pharm 2003;254:271-80 (Pubitemid 36298836)
103. Pillai O, Nair V, Panchagnula R. Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers. Int J Pharm 2004;269:109-20 (Pubitemid 38032828)
104. Li Y, Quan Y, Zang L, et al. Trypsin as a novel potential absorption enhancer for improving the transdermal delivery of macromolecules. J Pharm Pharmacol 2009;61:1005-12
105. Rastogi R, Anand S, Dinda AK, Koul V. Investigation on the synergistic effect of a combination of chemical enhancers and modulated iontophoresis for transdermal delivery of insulin. Drug Dev Ind Pharm 2010;36:993-1004
106. Rastogi SK, Singh J. Effect of chemical penetration enhancer and iontophoresis on the in vitro percutaneous absorption enhancement of insulin through porcine epidermis. Pharm Dev Technol 2005;10:97-104 (Pubitemid 40315533)
107. Kanikkannan N, Singh J, Ramarao P. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue. J Control Release 1999;59:99-105 (Pubitemid 29187197)
108. Kari B. Control of blood-glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes 1986;35:217-21 (Pubitemid 16121542)
109. Tomohira Y, Machida Y, Onishi H, Nagai T. Iontophoretic transdermal absorption of insulin and calcitonin in rats with newly-devised switching technique and addition of urea. Int J Pharm 1997;155:231-9 (Pubitemid 27380409)
110. Abla N, Naik A, Guy RH, Kalia YN. Iontohoresis: clinical applications and future challenges. In: Smith EW, Maibach HI, editors, Percutaneous penetration enhancers. 2nd edition; Taylor & Francis, Bristol PA, USA. 2005
111. Murthy SN, Zhao YL, Hui SW, Sen A. Synergistic effect of anionic lipid enhancer and electroosmosis for transcutaneous delivery of insulin. Int J Pharm 2006;326:1-6 (Pubitemid 44647734)
112. Kogure K, Yamamoto M, Watanabe M, et al. Transdermal delivery of insulin-encapsulated liposomes via iontophoresis. Yakugaku Zasshi 2008;128:81-2
113. Chen HB, Zhu HD, Zheng JN, et al. Iontophoresis-driven penetration of nanovesicles through microneedleinduced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 2009;139:63-72
114. Torres-Lugo M, Peppas NA. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000;21:1191-6 (Pubitemid 30195716)
115. Lee WA, Ennis RD, Longenecker JP, Bengtsson P. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm Res 1994;11:747-50 (Pubitemid 24171773)
116. Chang SL, Hofmann GA, Zhang L, et al. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 2000;200:107-13 (Pubitemid 30177255)
117. Morimoto K, Iwakura Y, Nakatani E, et al. Effect of proteolytic-enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats. J Pharm Pharmacol 1992;44:216-18
118. Nakamura K, Katagai K, Mori K, et al. Transdermal administration of salmon calcitonin by pulse depolarization-iontophoresis in rats. Int J Pharm 2001;218:93-102 (Pubitemid 32406160)
119. Santi P, Colombo P, Bettini R, et al. Drug reservoir composition and transport of salmon calcitonin in transdermal iontophoresis. Pharm Res 1997;14:63-6 (Pubitemid 27113316)
120. Thysman S, Hanchard C, Preat V. Human calcitonin delivery in rats by iontophoresis. J Pharm Pharmacol 1994;46:725-30 (Pubitemid 24289660)
121. Santi P, Volpato NM, Bettini R, et al. Transdermal iontophoresis of salmon calcitonin can reproduce the hypocalcemic effect of intravenous administration. Farmaco 1997;52:445-8 (Pubitemid 27479500)
122. Suzuki Y, Iga K, Yanai S, et al. Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1-34). J Pharm Pharmacol 2001;53:1227-34 (Pubitemid 32904017)
123. Suzuki Y, Nagase Y, Iga K, et al. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34). J Pharm Sci 2002;91:350-61 (Pubitemid 34137357)
124. Bhatia KS, Singh J. Effect of dimethylacetamide and 2-pyrrolidone on the iontophoretic permeability of LHRH through porcine skin. Drug Dev Ind Pharm 1997;23:1215-18 (Pubitemid 28030022)
125. Bhatia KS, Gao S, Singh J. Effect of penetration enhancers and iontophoresis on the FT-IR spectroscopy and LHRH permeability through porcine skin. J Control Release 1997;47:81-9 (Pubitemid 27154403)
126. Bhatia KS, Singh J. Mechanism of transport enhancement of LHRH through porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies. Pharm Res 1998;15:1857-62 (Pubitemid 29034834)
127. Bhatia KS, Singh J. Synergistic effect of iontophoresis and a series of fatty acids on LHRH permeability through porcine skin. J Pharm Sci 1998;87:462-9 (Pubitemid 28175808)
128. Bhatia KS, Singh J. Effect of linolenic acid ethanol or limonene ethanol and iontophoresis on the in vitro percutaneous absorption of LHRH and ultrastructure of human epidermis. Int J Pharm 1999;180:235-50 (Pubitemid 29238207)
129. Chen LLH, Chien YW. Transdermal iontophoretic permeation of luteinizing hormone releasing hormone: characterization of electric parameters. J Control Release 1996;40:187-98 (Pubitemid 26238371)
130. Heit MC, Monteiro-Riviere NA, Jayes FL, Riviere JE. Transdermal iontophoretic delivery of Luteinizing-Hormone-Releasing Hormone (LHRH) - Effect of repeated administration. Pharm Res 1994;11:1000-3 (Pubitemid 24227646)
131. Heit MC, Williams PL, Jayes FL, et al. Transdermal iontophoretic peptide delivery: in vitro and in vivo studies with luteinizing hormone releasing hormone. J Pharm Sci 1993;82:240-3 (Pubitemid 23150401)
132. Bayon AMR, Guy RH. Iontophoresis of nafarelin across human skin in vitro. Pharm Res 1996;13:798-800 (Pubitemid 26156231)
133. Meyer BR, Kreis W, Eschbach J, et al. Successful transdermal administration of therapeutic doses of a polypeptide to normal human volunteers. Clin Pharmacol Ther 1988;44:607-12 (Pubitemid 19036610)
134. Meyer BR, Kreis W, Eschbach J, et al. Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin Pharmacol Ther 1990;48:340-5 (Pubitemid 20362266)
135. Miller LL, Kolaskie CJ, Smith GA, Rivier J. Transdermal iontophoresis of gonadotropin releasing hormone (LHRH) and two analogues. J Pharm Sci 1990;79:490-3 (Pubitemid 20221392)
136. Lelawongs P, Liu JC, Chien YW. Transdermal iontophoretic delivery of Arginine-Vasopressin. 2. Evaluation of electrical and operational factors. Int J Pharm 1990;61:179-88 (Pubitemid 20209072)
137. Banga AK, Katakam M, Mitra R. Transdermal iontophoretic delivery and degradation of Vasopressin across human cadaver skin. Int J Pharm 1995;116:211-16
138. Nakakura M, Terajima M, Kato Y, et al. Effect of iontophoretic patterns on in-vivo antidiuretic response to Desmopressin Acetate administered transdermally. J Drug Target 1995;2:487-92
139. Nakakura M, Kato Y, Hayakawa E, et al. Effect of pulse on iontophoretic delivery of desmopressin acetate in rats. Biol Pharm Bull 1996;19:738-40 (Pubitemid 26187887)
140. Nakakura M, Kato Y, Ito K. Prolongation of antidiuretic response to desmopressin acetate by iontophoretic transdermal delivery in rats. Biol Pharm Bull 1997;20:537-40 (Pubitemid 27250640)
141. Kumar S, Char H, Patel S, et al. In vivo transdermal iontophoretic delivery of Growth-Hormone Releasing-Factor Grf (1-44) in hairless guinea-pigs. J Control Release 1992;18:213-20
142. Ellens H, Lai ZP, Marcello J, et al. Transdermal iontophoretic delivery of [H-3]GHRP in rats. Int J Pharm 1997;159:1-11 (Pubitemid 28062804)
143. Bushara KO, Park DM, Jones JC, Schutta HS. Botulinum toxin-a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 1996;21:276-8 (Pubitemid 26380193)
144. Gregoriou S, Rigopoulos D, Makris M, et al. Effects of botulinum toxin-A therapy for palmar hyperhidrosis in plantar sweat production. Dermatol Surg 2010;36:496-8
145. Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007;56:604-11 (Pubitemid 46400197)
146. Schnider P, Binder M, Kittler H, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 1999;140:677-80 (Pubitemid 29191388)
147. Kavanagh GM, Oh C, Shams K. BOTOX (R) delivery by iontophoresis. Br J Dermatol 2004;151:1093-5
148. Kavanagh GM, Shams K. Delivery of Botox (R) by iontophoresis: reply from authors. Br J Dermatol 2005;153:1076
149. Woolery-Lloyd H, Elsaie ML, Avashia N. Inguinal hyperhidrosis misdiagnosed as urinary incontinence: treatment with botulinum toxin A. J Drugs Dermatol 2008;7:293-5
150. Pacini S, Gulisano M, Punzi T, Ruggiero M. Transdermal delivery of Clostridium botulinum toxin type A by pulsed current iontophoresis. J Am Acad Dermatol 2007;57:1097-9 (Pubitemid 350087356)
151. Chang SL, Hofmann GA, Zhang L, et al. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J Control Release 2000;66:127-33 (Pubitemid 30160851)
152. Medi BM, Singh J. Electronically facilitated transdermal delivery of human parathyroid hormone (1-34). Int J Pharm 2003;263:25-33 (Pubitemid 37087929)
153. Riviere JE, Monteiro-Riviere NA, Rogers RA, et al. Pulsatile transdermal delivery of LHRH using electroporation. J Control Release 1995;36:229-33
154. Badkar AV, Banga AK. Electrically enhanced transdermal delivery of a macromolecule. J Pharm Pharmacol 2002;54:907-12 (Pubitemid 34763834)
155. Smyth HD, Becket G, Mehta S. Effect of permeation enhancer pretreatment on the iontophoresis of luteinizing hormone releasing hormone (LHRH) through human epidermal membrane (HEM). J Pharm Sci 2002;91:1296-307 (Pubitemid 34651191)
156. Wu XM, Todo H, Sugibayashi K. Enhancement of skin permeation of high molecular compounds by a combination of microneedle pretreatment and iontophoresis. J Control Release 2007;118:189-95 (Pubitemid 46329739)
157. Katikaneni S, Badkar A, Nema S, Banga AK. Molecular charge mediated transport of a 13 kD protein across microporated skin. Int J Pharm 2009;378:93-100
158. Katikaneni S, Li G, Badkar A, Banga AK. Transdermal delivery of a approximately 13 kDa protein-an in vivo comparison of physical enhancement methods. J Drug Target 2010;18:141-7
159. Badkar AV, Smith AM, Eppstein JA, Banga AK. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats. Pharm Res 2007;24:1389-95 (Pubitemid 46876496)